234 related articles for article (PubMed ID: 36578948)
1. DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml.
Sun H; Du F; Liu Y; Li Q; Liu X; Wang T
Front Oncol; 2022; 12():925186. PubMed ID: 36578948
[TBL] [Abstract][Full Text] [Related]
2. Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer.
Ma XZ; Lv K; Sheng JL; Yu YX; Pang PP; Xu MS; Wang SW
Oncol Lett; 2019 Mar; 17(3):3077-3084. PubMed ID: 30867737
[TBL] [Abstract][Full Text] [Related]
3. The Assessment of Prostate Cancer Aggressiveness Using a Combination of Quantitative Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Zhu G; Luo J; Ouyang Z; Cheng Z; Deng Y; Guan Y; Du G; Zhao F
Cancer Manag Res; 2021; 13():5287-5295. PubMed ID: 34239327
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
5. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
[No Abstract] [Full Text] [Related]
6. Multiparametric Magnetic Resonance Imaging in Evaluation of Clinically Significant Prostate Cancer.
Ingole SM; Mehta RU; Kazi ZN; Bhuyar RV
Indian J Radiol Imaging; 2021 Jan; 31(1):65-77. PubMed ID: 34316113
[No Abstract] [Full Text] [Related]
7. High-temporal resolution DCE-MRI improves assessment of intra- and peri-breast lesions categorized as BI-RADS 4.
Liu Y; Wang S; Qu J; Tang R; Wang C; Xiao F; Pang P; Sun Z; Xu M; Li J
BMC Med Imaging; 2023 Apr; 23(1):58. PubMed ID: 37076817
[TBL] [Abstract][Full Text] [Related]
8. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
Schimmöller L; Quentin M; Arsov C; Hiester A; Buchbender C; Rabenalt R; Albers P; Antoch G; Blondin D
Eur Radiol; 2014 Oct; 24(10):2582-9. PubMed ID: 24972954
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers.
Abreu-Gomez J; Lim C; Cron GO; Krishna S; Sadoughi N; Schieda N
Abdom Radiol (NY); 2021 Sep; 46(9):4370-4380. PubMed ID: 33818626
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of prostate cancer lesions in the Transition Zone by diffusion-weighted MRI.
Bao J; Wang X; Hu C; Hou J; Dong F; Guo L
Eur J Radiol Open; 2017; 4():123-128. PubMed ID: 29034282
[TBL] [Abstract][Full Text] [Related]
12. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
Cindil E; Oner Y; Sendur HN; Ozdemir H; Gazel E; Tunc L; Cerit MN
Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of integrated
Zeng Y; Leng X; Liao H; Jiang G; Chen P
Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of parotid gland tumours: Application of SWI combined with DWI and DCE-MRI.
Xu Z; Chen M; Zheng S; Chen S; Xiao J; Hu Z; Lu L; Yang Z; Lin D
Eur J Radiol; 2022 Jan; 146():110094. PubMed ID: 34906852
[TBL] [Abstract][Full Text] [Related]
15. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
[TBL] [Abstract][Full Text] [Related]
16. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing T1-2 and T3a tumors of rectal cancer with texture analysis and functional MRI parameters.
Sun D; Wu X; Wang L; Li G; Huang J; Li Y
Diagn Interv Radiol; 2022 May; 28(3):200-207. PubMed ID: 35748201
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.
Wu YC; Xiao ZB; Lin XH; Zheng XY; Cao DR; Zhang ZS
World J Gastroenterol; 2020 Oct; 26(39):6057-6073. PubMed ID: 33132655
[TBL] [Abstract][Full Text] [Related]
19. Use of diffusion kurtosis imaging and quantitative dynamic contrast-enhanced MRI for the differentiation of breast tumors.
Li T; Yu T; Li L; Lu L; Zhuo Y; Lian J; Xiong Y; Kong D; Li K
J Magn Reson Imaging; 2018 Nov; 48(5):1358-1366. PubMed ID: 29717790
[TBL] [Abstract][Full Text] [Related]
20. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
